Sinovac Biotech, Ltd (SVA) Posts Q4 Loss of 10c/Share

Sinovac Biotech, Ltd (NASDAQ: SVA) reported Q4 EPS of ($0.10), $0.10 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $19 million versus the consensus estimate of $4.8 million.

For earnings history and earnings-related data on Sinovac Biotech, Ltd (SVA) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• Is Treasury selloff a major issue for stock market bulls?